title: [Prognostic value of clinical and pathological characteristics in 48 women with pseudomyxoma peritonei].
abstract: OBJECTIVE
  To investigate the clinic-pathological characteristics and prognosis of 48 female cases with peritoneal pseudomyxoma(PMP).
  
  
  METHODS
  The clinicopathologic features and follow-up data of 48 female patients with PMP diagnosed in the General Hospital of People's Liberation Army from Jan.1982 to Dec.2011 were retrospectively reviewed. The relationship between clinic-pathological characteristics and prognosis were analyzed using log-rank test and Cox proportional hazards model.
  
  
  RESULTS
  (1) Clinicopathologic features: the mean age of the 48 cases was 58.8 years (range from 24 to 79 years).
  
  
  METHODS
  abdominal distention and abdominal discomfort were the main symptoms. Imaging examinations showed nonspecific abdominal and pelvic lesions in most cases.
  
  
  METHODS
  all the 48 patients underwent laparotomy and cytoreductive surgery (CRS), in which 15(31%) patients with completeness of the cancer resection (CCR) -1, 24(50%) cases with CCR-2, and CCR-3 in 9(19%) cases. Six (12%) cases were treated by intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin, 20(42%) patients were treated with different options postoperative adjuvant chemotherapy. Pathological types:the cases were histologically classified into 3 subcategories:disseminated peritoneal adenomucinosis (DPAM), peritoneal mucinous carcinomatosis (PMCA), and PMCA with intermediate or discordant features (PMCA-I/D), which were 22(46%) cases, 9 (19%)cases and 17 (35%)cases, respectively. Appendiceal tumors: 44(92%) cases underwent appendectomy, in which 38 cases presented appendiceal tumors (including 20 cases of low-grade appendiceal mucinous adenoma and 18 cases of appendiceal mucinous adenocarcinoma), 2 cases were diagnosed as appendicitis, 4 cases with unknown pathologic diagnosis. And the other 4(8%) cases, who didn't undergo appendectomy at the first operation, presented peritoneal tumor recurrence and appendiceal mucinous tumors 1, 11, 32 and 85 months after surgery, respectively. Parenchymal organs involved: ovarian involving was happened in 34 (71%) patients including 15 cases with the right ovary involving, 13 cases in both sides, and 6 cases involving the left side. The other parenchymal organs in 10(21%) cases. (2) Prognostic factors: 11 patients died, 31 survived and 6 cases were lost to follow-up. The mean survival time was 99 months(ranged from 1 to 312 months). The 3-year, 5-year and 10-year survival rates were 73.3%, 68.0% and 46.6%, respectively. Univariate statistical analysis showed that age, pathological type and parenchymal involvement were significantly relationship with the survival time (all P < 0.05). But the operation times, appendiceal tumor type, ovarian involvement, CCR, intraperitoneal HIPEC and post-operative adjuvant chemotherapy were not significantly correlate with survival time (all P > 0.05). Multivariate analysis showed that age and pathologic type were independent prognostic factors(P < 0.05).
  
  
  CONCLUSIONS
  No specific clinical features presented in PMP. CRS with HIPEC should the recommended treatment. Both ovaries exploration and appendectomy should be carried out routinely in CRS. The 10-year overall survival of PMP is low. Age, pathological type and parenchymal organs involvement other than ovarian are correlated with the prognosis. And the pathological type and age are independent prognostic factors of PMP.
authors.affiliation: Department of Pathology, the General Hospital of People's Liberation Army,Beijing 100853, China.
authors.forename: Yi-yan
authors.initials: YY
authors.lastname: Lu
authors.forename: Ai-tao
authors.initials: AT
authors.lastname: Guo
authors.forename: Ai-jun
authors.initials: AJ
authors.lastname: Liu
authors.forename: Huai-yin
authors.initials: HY
authors.lastname: Shi
mesh_terms: D002288:Adenocarcinoma, Mucinous / Q000175:diagnosis / Q000473:pathology* / Q000628:therapy; D000328:Adult; D000367:Age Factors; D000368:Aged; D001062:Appendectomy; D001063:Appendiceal Neoplasms / Q000175:diagnosis / Q000473:pathology* / Q000628:therapy; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D010534:Peritoneal Neoplasms / Q000175:diagnosis / Q000473:pathology* / Q000628:therapy; D011379:Prognosis; D011553:Pseudomyxoma Peritonei / Q000175:diagnosis / Q000473:pathology* / Q000628:therapy; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D002945:Cisplatin